Or register here

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

Vaso-Occlusive Crises and Costs of Sickle Cell Disease in Patients With Commercial, Medicaid and Medicare Insurance – The Perspective of Private and Public Payers

key information

source: Journal of Medical Economics

year: 2020

authors: Nirmish R. Shah, Menaka Bhor, Dominick Latremouille-Viau, Vikash Kumar Sharma, Gary A. Puckrein, Patrick Gagnon-Sanschagrin, Ankur Khare, Mukesh Kumar Singh, Elizabeth Serra, Mikhaïl Davidson, Liou Xu, Annie Guerin

summary/abstract:

Aim:
To characterize vaso-occlusive crises (VOCs) and describe healthcare costs among commercially-insured, Medicaid-insured, and Medicare-insured patients with sickle cell disease (SCD).

Materials and Methods:
The IBM Truven Health MarketScan Commercial (2000-2018), Medicaid Analytic eXtract (2008–2014), and Medicare Research Identifiable Files (2012–2016) databases were used to identify patients with >=2 SCD diagnoses. Study measures were evaluated during a 12-month follow-up period, stratified by annual number of VOCs (i.e., 0, 1, and >=2).

Results:
Among 16,092 commercially-insured patients (mean age =36.7 years), 35.3% had 1+ VOCs. Mean annual total all-cause healthcare costs were $15,747, $27,194, and $64,555 for patients with 0, 1, and 2+ VOCs, respectively. Total all-cause healthcare costs were mainly driven by inpatient (0 VOC =31.0%, 1 VOC =53.1%, 2+ VOCs =65.4%) and SCD-related costs (0 VOC =56.4%, 1 VOC =78.4%, 2+ VOCs =93.9%).

Among 18,287 Medicaid-insured patients (mean age =28.5 years, fee-for-service =50.2%), 63.9% had 1+ VOCs. Mean annual total all-cause healthcare costs were $16,750, $29,880, and $64,566 for patients with 0, 1, and 2+ VOCs, respectively. Inpatient costs (0 VOC =37.2%, 1 VOC =64.3%, 2+ VOCs =72.9%) and SCD-related costs (0 VOC =60.9%, 1 VOC =73.8%, 2+ VOCs =92.2%) accounted for a significant proportion of total all-cause healthcare costs.

Among 15,431 Medicare-insured patients (mean age =48.2 years), 55.1% had 1+ VOCs. Mean annual total all-cause healthcare costs were $21,877, $29,250, and $58,308 for patients with 0, 1, and >=2 VOCs, respectively. Total all-cause healthcare costs were mainly driven by inpatient (0 VOC =47.9%, 1 VOC =54.9%, 2+ VOCs =67.5%) and SCD-related costs (0 VOC =74.9%, 1 VOC =84.4%, 2+ VOCs =95.3%).

Conclusions:
A high proportion of patients experienced VOCs across payers. Furthermore, inpatient and SCD-related costs accounted for a significant proportion of total all-cause healthcare costs, which increased with VOC frequency.

organization: Duke Adult Comprehensive Sickle Cell Center, USA; Novartis Pharmaceuticals Corporation, USA; Analysis Group, Inc., Canada; Novartis Healthcare Pvt. Ltd., India; National Minority Quality Forum, USA

DOI: 10.1080/13696998.2020.1813144

read more

Log in

Enter the code

Join the community

Trusted Resources Home

Education & Research

People & Places

News & Events

Videos & Visuals

Community Center

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Vaso-Occlusive Crises and Costs of Sickle Cell Disease in Patients With Commercial, Medicaid and Medicare Insurance – The Perspective of Private and Public Payers

Related Content

Powered by

Log in

Enter Phone Number

Enter the code

Join the community

Trusted Resources Home

Education & Research

People & Places

News & Events

Videos & Visuals

Community Center

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Vaso-Occlusive Crises and Costs of Sickle Cell Disease in Patients With Commercial, Medicaid and Medicare Insurance – The Perspective of Private and Public Payers

Related Content

Powered by

Support for this site is provided by